Dreismann Heinrich
Known title: DirectorCIK: 0001379372
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Quantum Cyber Reports Audited Financials and Refines Strategic Focus. Quantum Cyber has released audited and reviewed financial statements for its Bridgeport Manufacturing acquisition. In a new investor presentation, the firm highlighted a sharpened focus on quantum navigation, interceptor drones, and U.S. manufacturing. These updates outline the company’s progress on the acquisition and its strategic priorities moving forward.
Transaction History
| MYGN | ▲ Buy | Grant | 59,701 | $0 | 6/4/2026 | View on chart |
| QUCY | ▲ Buy | Grant | 45,000 | $0 | 2/13/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 49,796 | $0 | 6/5/2025 | View on chart |
| MYGN | ▼ Sell | Open Market | 10,000 | $271K | 9/9/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 15,695 | $0 | 6/6/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 15,151 | $0 | 6/1/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 17,275 | $0 | 6/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.